Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05648487 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2022 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Interventions: HIPEC, anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery (Drug) to HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery (Drug)v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the Safety and Efficacy of HIPEC Combined With Sintilimab for Gastric Cancer Patients with Peritoneal Metastasis.
Trial Details
NCT Number NCT05648487
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions
(from sponsor)		 Gastric Cancer
Related terms Stomach Neoplasms
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov